Spun off from Abbot Laboratories in 2013, AbbVie has grown into a valuable player in the healthcare space. The company’s portfolio includes Humira, Rinvoq, and Skyrizi, treatments acquired through its ...

U.S. stocks fall on Friday after the White House says Canada, Mexico and China tariffs will start Saturday. Still, major indexes finish January ahead.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

The S&P 500 declined by 0.5% on Friday, Jan. 31, as investors digested the White House’s proposed tariffs on Canada, China, and Mexico.

Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, Intel edges higher after revenue projections miss analysts’ estimates, and Chevron posts ...

AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for Skyrizi and Rinvoq ...

US benchmark equity indexes ended lower Friday as markets analyzed the latest reading of the Federal Reserve's preferred inflation metric, as well as corporate earnings. * Official data showed that US ...

AbbVie’s ABBV 2024 revenue grew 4.6% on a constant currency basis, with 2025 guidance of 5.7% growth and new 2027 guidance for combined sales of immunology drug Skyrizi and Rinvoq of $31 billion (up ...

AbbVie reported strong Q4 results, driven by Skyrizi, Rinvoq, neuroscience products, and eye care. Click here to find out why ...

AbbVie (NYSE: ABBV) stock rose 4.2% after the drugmaker forecast 2025 profit above estimates, as strong sales of its newer ...

ABBV's fourth-quarter earnings and sales beat estimates. Management raises the 2027 forecast for newer immunology drugs to ...

AbbVie's acquisition of Allergan significantly increased the firm's debt level. We expect the firm's net debt position to peak at close to $70 billion in 2020 but given the strong cash flows of AbbVie ...